A Phase 2 interventional study of Delpazolid and Bedaquiline, Delamanid, Moxifloxacin in Infections and Infestations and Pulmonary Tuberculosis, sponsored by LigaChem Biosciences, Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by LigaChem Biosciences, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Tuberculosis, Pulmonary with a site in Tanzania — 4 open to participants now, 6 under way, none of them phase 3. Tuberculosis, Pulmonary · Tanzania.
Among the 17 studies in Tuberculosis, Pulmonary with a site in Tanzania, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2021, is one of 12 in phase 2, and was the 9th registered.
320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.
Browse Tuberculosis, Pulmonary studies →4 of the 17 studies in Tuberculosis, Pulmonary with a site in Tanzania are open now. Recruiting first, the newest first:
Global Alliance for TB Drug Development · Sites in Tanzania, South Africa
Ages 18–65
University College, London · Sites in Tanzania, Moldova, South Africa and 2 more countries
Ages 18+
Michael Hoelscher · Sites in Tanzania, Gabon, Malawi and 3 more countries
Ages 18–65
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in Tanzania, Argentina, Australia and 13 more countries
Ages 13+
A study can be open while its sites in Tanzania have not opened yet or have stopped. Only those recruiting at a site in Tanzania →
Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 2
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.
Median enrollment 365 across the 15 interventional studies, 1,800 across the 2 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 8 most frequent:
LigaChem Biosciences, Inc. is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
LigaChem Biosciences, Inc. has 2 studies filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
3 of the studies in Tuberculosis, Pulmonary with a site in Tanzania that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06114628University College, LondonPlatform Assessing Regimens and Durations In a Global Multisite Consortium for TB | 2027-02-24 |
| NCT07672405Global Alliance for TB Drug DevelopmentSorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB | 2027-05-28 |
| NCT05807399Michael HoelscherPanACEA - STEP2C -01 | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Tuberculosis, Pulmonary with a site in Tanzania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin, compared to standard-dose Bedaquiline, Delamanid and Moxifloxacin alone
This will be an open label Phase IIb dose-finding, randomized, controlled study with a duration of 16 weeks of experimental therapy of Delpazolid(DZD) - Bedaquiline/Delamanid/ Moxifloxacin (BDM) in adult patients with newly diagnosed, smear positive, uncomplicated, drug sensitive pulmonary tuberculosis (TB) to evaluate the safety, efficacy, tolerability, pharmacokinetics and exposure/response-relationship of different doses of delpazolid in combination with bedaquiline, delamanid and moxifloxacin.
Participants will be randomized to one of five arms containing BDM standard dose with different doses of DZD.
320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.
This study's enrollment of 76 is below the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.
Browse Tuberculosis, Pulmonary studies →LigaChem Biosciences, Inc. is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant is either unable to conceive/father children AND/OR his/her partner is unable to conceive/father children AND/OR they will consent to be using effective methods of when engaging in heterosexual intercourse, as defined below:
a. Non-: i. Female participant/sexual partner of male participant: Bilateral oophorectomy, and/or hysterectomy or bilateral tubal ligation more than 12 months ago and/or has been with a history of no menses for at least 12 consecutive months ii. Male participant/sexual partner of female participant: Vasectomised or has had a bilateral orchidectomy minimally three months prior to screening iii. Male participants having a pregnant female partner or a male sexual partner: At least one barrier method has to be used in this case. b. Effective contraception methods: i. Female participants: Two methods, including methods that the patient's sexual partner(s) use. At least one must be a barrier method. Contraception must be practised for at least until 12 weeks after the last dose of DZD. ii. Male participants: Two methods, including methods that the patient's female sexual partner(s) use. At least one must be a barrier method. Effective contraception must be ensured for at least 16 weeks after the last dose of DZD.
Note: hormone-based contraception alone may not be reliable when taking RIF during continuation phase; therefore, hormone-based contraceptives alone cannot be used by female participants/female partners of male participants to prevent pregnancy.
Exclusion Criteria:
The patient is infected with with a \<220 cells/mm3. If >220 cells/mm3, patients will be included only if any of the following is applicable:
The patient has a history of, or current evidence of cardiovascular metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, , or any other condition that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:
Any of the following laboratory findings at screening:
findings in the screening ECG: (one or more):
Restricted medication:
Unable or unwilling to abide by the requirements regarding restricted medication or have taken restricted medication as described under section 12.6, page 58. Restricted medication includes the following drug classes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will not administered * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily
Drug: Bedaquiline, Delamanid, Moxifloxacin
Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will be dosed 400 mg orally once daily * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily
Drug: Delpazolid · Drug: Bedaquiline, Delamanid, Moxifloxacin
Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will be dosed 800 mg orally once daily * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily
Drug: Delpazolid · Drug: Bedaquiline, Delamanid, Moxifloxacin
Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will be dosed 1200 mg orally once daily * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily
Drug: Delpazolid · Drug: Bedaquiline, Delamanid, Moxifloxacin
Participants receive the following medication for the duration of 16weeks together with food. * Delpazolid : Will be dosed 800 mg orally twice daily * Bedaquiline: will be dosed as per the licensed dose: 400 mg orally once daily for the first 14 days, then 200 mg three times a week. * Delamanid: will be dosed as per the licensed dose: 200 mg orally twice daily doses of 100 mg. * Moxifloxacin: will be dosed as per the licensed dose: 400 mg orally once daily
Drug: Delpazolid · Drug: Bedaquiline, Delamanid, Moxifloxacin
Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.
Also known as: LCB01-0371
Drug pages: BedaquilineStudies of BedaquilineBedaquiline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · OPC-67683Studies of OPC-67683OPC-67683 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MoxifloxacinStudies of MoxifloxacinMoxifloxacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
Also known as: BDM
Safety Outcome : Proportion of Patients Experiencing Adverse Event
Participants with ≥ 1 TEAE, by severity, related Adverse events: possibly, probably, or definitely related to study drugs
Time frame: week0 - week52
Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_AUC0-24
The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.
Time frame: Week 0 - Week 16
Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmax
The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.
Time frame: Week 0 - Week 16
Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmin
The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.
Time frame: Week 0 - Week 16
Efficacy Outcome: BD MGIT960® Liquid Media Culture Results
Summary of Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Positivity in BD MGIT960® Liquid Media - Intent to Treat Population Sputum samples were collected for BD MGIT960® Liquid Media culture at all time points during the treatment and follow-up phases, and this table shows culture results, which are reported as: Positive, Negative, Contaminated, Missing. Note: Contaminated cultures are shown as contaminated for the purpose of the overall result but are counted as missing for calculating summary statistics. The data recorded as 'Positive for MTB Complex with Contamination' are included as 'Positive' for MGIT result. However, the data from mean and median calculations for TTP (Time to positive) due to contamination.
Time frame: Week 0 - Week 16
Efficacy Outcome: Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Positivity in BD MGIT960® Liquid Media
The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by time to positivity (TTP) in BD MGIT 960® liquid culture described by nonlinear mixed-effects methodology. Sputum samples were collected for BD MGIT960® Liquid Media culture at all time points during the treatment and follow-up phases, and this table shows TTP results.
Time frame: Week 0 - Week 16
Efficacy Outcome: Loewenstein-Jensen Solid Media Culture Results
Summary of Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Culture Conversion in Loewenstein-Jensen Solid Media - Intent-to-Treat Population Sputum samples were collected for Loewenstein-Jensen Solid Media culture at at Week 0, Week 8, Week 12, Week 6 during the treatment and follow-up phases, and this table shows culture results, which are reported as: Positive, Negative, Contaminated, Missing.
Time frame: Week 0 - Week 16
Efficacy Outcome: The Proportion Converted by Day Corresponding to End of Each Week
Culture conversion was defined as 2 negative cultures without an intervening positive culture. Time was measured as time on treatment until the first negative culture (up to Week 16 Visit). 'Converted by Week x' shows proportion converted by day corresponding to end of each week, e.g., Week 2 = Day 14.
Time frame: Week 0 - Week 16
Efficacy Outcome: Time to Culture Conversion
Time to culture conversion was defined as 2 negative cultures without an intervening positive culture. Time was measured as time on treatment until the first negative culture (up to Week 16 Visit).
Time frame: Week 0 - Week 16
Efficacy Outcome : Relapse or Reinfection
A participant was positive for relapse or reinfection if they converted to culture negative by Week 8 and had 2 consecutive positive cultures after Week 16 of randomization, without an intervening negative.
Time frame: Week0 - Week52
| Milestone | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Started | 15 | 15 | 15 | 16 | 15 |
| Received ≥ 1 dose of study drug | 15 | 15 | 15 | 16 | 15 |
| Completed | 15 | 15 | 13 | 16 | 14 |
| Not completed | 0 | 0 | 2 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 1 |
Participants with ≥ 1 TEAE, by severity, related Adverse events: possibly, probably, or definitely related to study drugs
| Participants | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| TEAE (total) | 8 | 7 | 7 | 6 | 9 |
| Grade 1 (mild) | 4 | 3 | 0 | 0 | 1 |
| Grade 2 (moderate) | 4 | 4 | 5 | 5 | 7 |
| Grade 3 (severe) | 0 | 0 | 1 | 1 | 3 |
| Grade 4 (life-threatening) | 0 | 0 | 2 | 0 | 0 |
| Unrelated | 5 | 3 | 6 | 3 | 6 |
| Unlikely related | 0 | 1 | 1 | 1 | 1 |
| Possibly related | 2 | 1 | 0 | 1 | 4 |
| Probably related | 0 | 1 | 1 | 1 | 0 |
| Definitely related | 1 | 1 | 0 | 0 | 0 |
| SAE- Grade 3 (severe) | 0 | 0 | 0 | 0 | 2 |
| SAE-Grade 4 (life-threatening) | 0 | 0 | 1 | 0 | 0 |
| DZD-unrelated SAEs | 0 | 0 | 1 | 0 | 0 |
| DZD-related SAEs | 0 | 0 | 0 | 0 | 2 |
The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.
| mg/L*h | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_AUC0-24 | NA (NA to NA) | 10.1 (6.86 to 20.4) | 28.6 (15.1 to 76.7) | 47.0 (11.8 to 94.0) | 68.5 (28.8 to 198) |
The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.
| mg/L | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmax | NA (NA to NA) | 3.78 (2.92 to 4.45) | 7.72 (5.78 to 13.9) | 13.7 (9.56 to 19.7) | 9.16 (7.56 to 13.4) |
The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by TTP (Time to positive) in BD MGIT960® liquid culture described by non linear mixed effects methodology. A population PK model was developed using NONMEM version 7.4.1. DZD PK is well-described by a two-compartment model with first-order absorption, first-order elimination and a proportional residual error. The final model included allometric scaling based on FFM.
| mg/L | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Efficacy Outcome: Exposure-response Analysis With TTP (Time to Positive)_Cmin | NA (NA to NA) | 0.00296 (0.000437 to 0.459) | 0.00948 (0.000439 to 0.810) | 0.00240 (0.000215 to 0.291) | 0.00400 (0.000157 to 0.564) |
Summary of Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Positivity in BD MGIT960® Liquid Media - Intent to Treat Population Sputum samples were collected for BD MGIT960® Liquid Media culture at all time points during the treatment and follow-up phases, and this table shows culture results, which are reported as: Positive, Negative, Contaminated, Missing. Note: Contaminated cultures are shown as contaminated for the purpose of the overall result but are counted as missing for calculating summary statistics. The data recorded as 'Positive for MTB Complex with Contamination' are included as 'Positive' for MGIT result. However, the data from mean and median calculations for TTP (Time to positive) due to contamination.
| Participants | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Week 0 — Positive | 15 | 15 | 15 | 16 | 15 |
| Week 0 — Negative | 0 | 0 | 0 | 0 | 0 |
| Week 0 — Contaminated | 0 | 0 | 0 | 0 | 0 |
| Week 0 — Missing | 0 | 0 | 0 | 0 | 0 |
| Week 1 — Positive | 15 | 14 | 15 | 15 | 15 |
| Week 1 — Negative | 0 | 1 | 0 | 1 | 0 |
| Week 1 — Contaminated | 0 | 0 | 0 | 0 | 0 |
| Week 1 — Missing | 0 | 0 | 0 | 0 | 0 |
| Week 2 — Positive | 15 | 14 | 14 | 16 | 15 |
| Week 2 — Negative | 0 | 1 | 1 | 0 | 0 |
| Week 2 — Contaminated | 0 | 0 | 0 | 0 | 0 |
| Week 2 — Missing | 0 | 0 | 0 | 0 | 0 |
| Week 3 — Positive | 15 | 13 | 12 | 15 | 15 |
| Week 3 — Negative | 0 | 2 | 1 | 0 | 0 |
| Week 3 — Contaminated | 0 | 0 | 0 | 1 | 0 |
| Week 3 — Missing | 0 | 0 | 2 | 0 | 0 |
| Week 4 — Positive | 13 | 13 | 13 | 14 | 12 |
| Week 4 — Negative | 2 | 2 | 1 | 2 | 3 |
| Week 4 — Contaminated | 0 | 0 | 0 | 0 | 0 |
| Week 4 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 5 — Positive | 14 | 12 | 11 | 13 | 12 |
| Week 5 — Negative | 1 | 3 | 2 | 3 | 3 |
| Week 5 — Contaminated | 0 | 0 | 0 | 0 | 0 |
| Week 5 — Missing | 0 | 0 | 2 | 0 | 0 |
| Week 6 — Positive | 9 | 9 | 12 | 10 | 12 |
| Week 6 — Negative | 5 | 6 | 2 | 6 | 3 |
| Week 6 — Contaminated | 1 | 0 | 0 | 0 | 0 |
| Week 6 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 7 — Positive | 9 | 8 | 5 | 8 | 8 |
| Week 7 — Negative | 6 | 7 | 9 | 8 | 7 |
| Week 7 — Contaminated | 0 | 0 | 0 | 0 | 0 |
| Week 7 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 8 — Positive | 6 | 6 | 5 | 2 | 7 |
| Week 8 — Negative | 9 | 9 | 9 | 13 | 7 |
| Week 8 — Contaminated | 0 | 0 | 0 | 1 | 1 |
| Week 8 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 9 — Positive | 5 | 4 | 3 | 3 | 2 |
| Week 9 — Negative | 10 | 11 | 11 | 13 | 11 |
| Week 9 — Contaminated | 0 | 0 | 0 | 0 | 1 |
| Week 9 — Missing | 0 | 0 | 1 | 0 | 1 |
| Week 10 — Positive | 4 | 3 | 1 | 3 | 3 |
| Week 10 — Negative | 10 | 12 | 12 | 13 | 11 |
| Week 10 — Contaminated | 1 | 0 | 1 | 0 | 1 |
| Week 10 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 11 — Positive | 3 | 2 | 1 | 1 | 2 |
| Week 11 — Negative | 11 | 12 | 13 | 14 | 13 |
| Week 11 — Contaminated | 1 | 1 | 0 | 1 | 0 |
| Week 11 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 12 — Positive | 2 | 0 | 0 | 0 | 2 |
| Week 12 — Negative | 12 | 15 | 14 | 16 | 13 |
| Week 12 — Contaminated | 1 | 0 | 0 | 0 | 0 |
| Week 12 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 13 — Positive | 0 | 0 | 0 | 0 | 3 |
| Week 13 — Negative | 15 | 15 | 14 | 15 | 12 |
| Week 13 — Contaminated | 0 | 0 | 0 | 1 | 0 |
| Week 13 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 14 — Positive | 1 | 0 | 0 | 0 | 2 |
| Week 14 — Negative | 13 | 15 | 12 | 14 | 11 |
| Week 14 — Contaminated | 1 | 0 | 2 | 2 | 2 |
| Week 14 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 15 — Positive | 1 | 0 | 0 | 0 | 1 |
| Week 15 — Negative | 14 | 15 | 13 | 16 | 14 |
| Week 15 — Contaminated | 0 | 0 | 1 | 0 | 0 |
| Week 15 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 16 — Positive | 0 | 0 | 0 | 0 | 1 |
| Week 16 — Negative | 14 | 15 | 14 | 16 | 14 |
| Week 16 — Contaminated | 1 | 0 | 0 | 0 | 0 |
| Week 16 — Missing | 0 | 0 | 1 | 0 | 0 |
The efficacy of DZD was evaluated by measuring the change in mycobacterial load over time on treatment as quantified by time to positivity (TTP) in BD MGIT 960® liquid culture described by nonlinear mixed-effects methodology. Sputum samples were collected for BD MGIT960® Liquid Media culture at all time points during the treatment and follow-up phases, and this table shows TTP results.
| days | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Week 0 | 5.6 ± 2.2 | 6.5 ± 4.1 | 7.2 ± 5.7 | 8.0 ± 9.0 | 5.9 ± 2.2 |
| Week 1 | 10.9 ± 3.2 | 13.0 ± 8.9 | 10.1 ± 3.8 | 11.1 ± 8.8 | 9.6 ± 3.3 |
| Week 2 | 13.3 ± 4.3 | 16.9 ± 9.9 | 15.4 ± 8.6 | 13.7 ± 7.8 | 12.2 ± 3.7 |
| Week 3 | 16.6 ± 6.5 | 18.0 ± 11.8 | 16.0 ± 8.4 | 14.2 ± 6.4 | 15.7 ± 8.2 |
| Week 4 | 19.1 ± 10.4 | 18.3 ± 10.3 | 18.7 ± 8.1 | 21.2 ± 10.1 | 19.8 ± 12.1 |
| Week 5 | 23.6 ± 9.2 | 24.4 ± 11.0 | 23.3 ± 10.1 | 25.3 ± 10.4 | 23.8 ± 10.8 |
| Week 6 | 27.3 ± 11.9 | 29.7 ± 11.4 | 2.74 ± 8.4 | 27.9 ± 12.1 | 26.9 ± 10.3 |
| Week 7 | 30.8 ± 11.7 | 31.6 ± 10.9 | 35.1 ± 9.7 | 33.6 ± 10.9 | 30.9 ± 12.5 |
| Week 8 | 33.3 ± 12.0 | 36.6 ± 8.9 | 36.3 ± 9.7 | 39.4 ± 7.5 | 33.2 ± 11.1 |
| Week 9 | 35.8 ± 10.3 | 37.7 ± 9.7 | 38.0 ± 8.3 | 37.0 ± 10.9 | 38.8 ± 7.8 |
| Week 10 | 36.4 ± 10.1 | 37.8 ± 9.1 | 40.5 ± 5.4 | 39.3 ± 7.3 | 39.7 ± 5.5 |
| Week 11 | 36.6 ± 11.5 | 40.1 ± 5.2 | 40.9 ± 4.3 | 41.4 ± 2.4 | 38.5 ± 9.4 |
| Week 12 | 38.5 ± 9.3 | 42.0 ± 0 | 42.0 ± 0 | 42.0 ± 0 | 40.0 ± 6.1 |
| Week 13 | 42.0 ± 0 | 42.0 ± 0 | 42.0 ± 0 | 42.0 ± 0 | 39.2 ± 7.3 |
| Week 14 | 39.9 ± 8.0 | 42.0 ± 0 | 42.0 ± 0 | 42.0 ± 0 | 39.4 ± 7.8 |
| Week 15 | 39.7 ± 8.9 | 42.0 ± 0 | 42.0 ± 0 | 42.0 ± 0 | 40.0 ± 7.8 |
| Week 16 | 42.0 ± 0 | 42.0 ± 0 | 42.0 ± 0 | 42.0 ± 0 | 40.0 ± 7.7 |
Summary of Changes in Mycobacterial Load Over Time on Treatment as Quantified by Time to Culture Conversion in Loewenstein-Jensen Solid Media - Intent-to-Treat Population Sputum samples were collected for Loewenstein-Jensen Solid Media culture at at Week 0, Week 8, Week 12, Week 6 during the treatment and follow-up phases, and this table shows culture results, which are reported as: Positive, Negative, Contaminated, Missing.
| Participants | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Week 0 — Positive | 14 | 15 | 15 | 16 | 15 |
| Week 0 — Negative | 1 | 0 | 0 | 0 | 0 |
| Week 0 — Contaminated | 0 | 0 | 0 | 0 | 0 |
| Week 0 — Missing | 0 | 0 | 0 | 0 | 0 |
| Week 8 — Positive | 4 | 2 | 3 | 1 | 3 |
| Week 8 — Negative | 11 | 12 | 11 | 15 | 12 |
| Week 8 — Contaminated | 0 | 1 | 0 | 0 | 0 |
| Week 8 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 12 — Positive | 2 | 0 | 0 | 0 | 1 |
| Week 12 — Negative | 13 | 15 | 14 | 16 | 14 |
| Week 12 — Contaminated | 0 | 0 | 0 | 0 | 0 |
| Week 12 — Missing | 0 | 0 | 1 | 0 | 0 |
| Week 16 — Positive | 0 | 0 | 0 | 0 | 1 |
| Week 16 — Negative | 14 | 15 | 14 | 16 | 14 |
| Week 16 — Contaminated | 1 | 0 | 0 | 0 | 0 |
| Week 16 — Missing | 0 | 0 | 1 | 0 | 0 |
Culture conversion was defined as 2 negative cultures without an intervening positive culture. Time was measured as time on treatment until the first negative culture (up to Week 16 Visit). 'Converted by Week x' shows proportion converted by day corresponding to end of each week, e.g., Week 2 = Day 14.
| percentage of participants | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Week 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 | 0 | 6.7 | 6.7 | 0 | 0 |
| Week 3 | 0 | 6.7 | 6.7 | 0 | 0 |
| Week 4 | 6.7 | 6.7 | 13.8 | 6.2 | 13.3 |
| Week 5 | 6.7 | 20.0 | 13.8 | 18.8 | 13.3 |
| Week 6 | 33.3 | 40.0 | 21.0 | 37.5 | 13.3 |
| Week 7 | 40.0 | 46.7 | 64.1 | 43.8 | 40.0 |
| Week 8 | 60.0 | 73.3 | 64.1 | 75.0 | 46.7 |
| Week 9 | 60.0 | 86.7 | 78.5 | 87.5 | 73.3 |
| Week 10 | 66.7 | 86.7 | 92.8 | 87.5 | 80.0 |
| Week 11 | 73.3 | 86.7 | 92.8 | 93.8 | 86.7 |
| Week 12 | 80.0 | 100 | 100 | 100 | 86.7 |
| Week 13 | 93.3 | 100 | 100 | 100 | 86.7 |
| Week 14 | 93.3 | 100 | 100 | 100 | 86.7 |
| Week 15 | 93.3 | 100 | 100 | 100 | 93.3 |
| Week 16 | 93.3 | 100 | 100 | 100 | 93.3 |
Time to culture conversion was defined as 2 negative cultures without an intervening positive culture. Time was measured as time on treatment until the first negative culture (up to Week 16 Visit).
| Days | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Efficacy Outcome: Time to Culture Conversion | 56.0 (42.0 to 84.0) | 56.0 (42.0 to 63.0) | 59.0 (49.0 to 63.0) | 56.0 (42.0 to 59.5) | 63.0 (49.0 to 70.0) |
A participant was positive for relapse or reinfection if they converted to culture negative by Week 8 and had 2 consecutive positive cultures after Week 16 of randomization, without an intervening negative.
| Participants | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| Conversion by Week 8 and no positive culture past week 12 | 9 | 11 | 10 | 12 | 5 |
| Conversion by Week 8 and positive culture past week 12 | 0 | 0 | 0 | 0 | 2 |
| Did not convert by Week 8 | 6 | 4 | 5 | 4 | 8 |
| Relapsed or reinfected | 0 | 0 | 0 | 0 | 0 |
| Death | 0 | 0 | 0 | 0 | 0 |
Collected over From Week 0 to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm1(D0) | 0/15 (0%) | 0/15 (0%) | 8/15 (53.3%) |
| Arm2(D400) | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Arm3(D800-OD) | 0/15 (0%) | 1/15 (6.7%) | 7/15 (46.7%) |
| Arm4(D1200) | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Arm5(D800-BD) | 0/15 (0%) | 2/15 (13.3%) | 9/15 (60%) |
| Event | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| GastritisGastrointestinal disorders | 0/15 | 0/15 | 0/15 | 0/16 | 1/15 |
| AnaemiaBlood and lymphatic system disorders | 0/15 | 0/15 | 0/15 | 0/16 | 1/15 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/15 | 0/15 | 1/15 | 0/16 | 0/15 |
| Event | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/15 | 0/15 | 3/15 | 2/16 | 4/15 |
| VomitingGastrointestinal disorders | 2/15 | 0/15 | 1/15 | 2/16 | 3/15 |
| AnemiaBlood and lymphatic system disorders | 0/15 | 0/15 | 1/15 | 0/16 | 2/15 |
| TachycardiaCardiac disorders | 0/15 | 0/15 | 0/15 | 0/16 | 2/15 |
| Electrocardiogram QT prolongedInvestigations | 2/15 | 2/15 | 2/15 | 1/16 | 1/15 |
| Gamma glutamyl transferase increasedInvestigations | 0/15 | 1/15 | 0/15 | 0/16 | 2/15 |
| HeadacheNervous system disorders | 0/15 | 0/15 | 1/15 | 1/16 | 2/15 |
| TachypnoeaRespiratory, thoracic and mediastinal disorders | 0/15 | 0/15 | 2/15 | 0/16 | 0/15 |
| PyrexiaGeneral disorders | 0/15 | 1/15 | 1/15 | 1/16 | 1/15 |
| ConjunctivitisInfections and infestations | 0/15 | 0/15 | 1/15 | 0/16 | 1/15 |
Intent-to-Treat Population and Safety Population
| Age, Continuous(years) | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) | Total |
|---|---|---|---|---|---|---|
| Mean | 35.6 ± 10.3 | 39.7 ± 9.0 | 35.1 ± 11.3 | 34.1 ± 7.1 | 33.3 ± 8.4 | 35.5 ± 9.3 |
| Sex: Female, Male(Participants) | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 0 | 3 | 7 | 4 | 16 |
| Male | 13 | 15 | 12 | 9 | 11 | 60 |
| Ethnicity (NIH/OMB)(Participants) | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 14 | 15 | 14 | 16 | 15 | 74 |
| Unknown or Not Reported | 1 | 0 | 1 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 15 | 15 | 15 | 16 | 15 | 76 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m2) | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) | Total |
|---|---|---|---|---|---|---|
| Mean | 18.2 ± 1.8 | 18.8 ± 2.1 | 20.0 ± 3.8 | 20.2 ± 3.0 | 20.0 ± 3.5 | 19.5 ± 3.0 |
| HIV status(Participants) | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) | Total |
|---|---|---|---|---|---|---|
| Negative | 13 | 14 | 12 | 13 | 13 | 65 |
| Positive | 2 | 1 | 3 | 3 | 2 | 11 |
| GeneXpert CT results(Participants) | Arm1(D0) | Arm2(D400) | Arm3(D800-OD) | Arm4(D1200) | Arm5(D800-BD) | Total |
|---|---|---|---|---|---|---|
| < 16 ; high bacili (TB) load | 3 | 3 | 3 | 3 | 3 | 15 |
| ≥ 16 ; low bacili (TB) load | 12 | 12 | 12 | 13 | 12 | 61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Deidentified individual patient data, that underlie the results in published article(s) based on data from the trial which including text, tables, figures will be presented to various stakeholders. This reported will be presented to various stakeholder during various forums or meetings. First esults will be disclosed to participants, staff and our site Community Advisory Board. Thereafter we would invite several stakeholders from the community or visit their establishments to review study results. Simultaneously, the studying findings report will be sent to the various regulatory authorities, including the National Department of Health (NDoH). With NDoH and its divisions we will establish needs for further engagement and suggestions for policy or programmatic changes.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: PD will be provided 1 - 2 years after and up to 5 years after the publication of the article on the results of the trial
Access criteria: IPD access will be provided for analyses of related to the aims of research described in the protocol and for individual patient data meta-analyses to researchers who provide a methodologically sound proposal to yhlee@ligachembio.com
Ran from Oct 2021 to primary completion in Jan 2023, 14 months.
Results were first posted in Oct 2024, 1 year 9 months after primary completion.
Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delpazolid
LigaChem Biosciences, Inc.